American Century Companies Inc. grew its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 23.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 330,514 shares of the company’s stock after buying an additional 63,550 shares during the period. American Century Companies Inc. owned 0.34% of Intellia Therapeutics worth $7,397,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in NTLA. Blue Trust Inc. lifted its holdings in Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in Intellia Therapeutics by 22.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares during the period. GAMMA Investing LLC grew its stake in Intellia Therapeutics by 1,322.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock valued at $59,000 after buying an additional 2,459 shares in the last quarter. EntryPoint Capital LLC raised its holdings in Intellia Therapeutics by 61.1% during the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after acquiring an additional 1,563 shares during the period. Finally, AdvisorNet Financial Inc raised its holdings in Intellia Therapeutics by 63.5% during the 2nd quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock valued at $114,000 after acquiring an additional 1,980 shares during the period. Institutional investors own 88.77% of the company’s stock.
Intellia Therapeutics Stock Performance
Shares of NTLA opened at $21.46 on Tuesday. Intellia Therapeutics, Inc. has a fifty-two week low of $19.21 and a fifty-two week high of $34.87. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of -4.00 and a beta of 1.77. The firm has a 50 day moving average price of $23.17 and a 200-day moving average price of $24.02.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on NTLA. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. JPMorgan Chase & Co. cut their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. Truist Financial reissued a “buy” rating and issued a $120.00 price target on shares of Intellia Therapeutics in a report on Monday, June 24th. Finally, Stifel Nicolaus decreased their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $61.77.
View Our Latest Stock Analysis on NTLA
Intellia Therapeutics Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Recommended Stories
- Five stocks we like better than Intellia Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- The Average 401k Balance by Age Explained
- How to Invest in Biotech Stocks
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Why Invest in High-Yield Dividend Stocks?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.